Two roads for oncolytic immunotherapy development

Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) administration. While this may allow easy access to metastatic lesions, there is limited data s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Howard L., Bommareddy, Praveen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359832/
https://www.ncbi.nlm.nih.gov/pubmed/30709365
http://dx.doi.org/10.1186/s40425-019-0515-2
_version_ 1783392366004011008
author Kaufman, Howard L.
Bommareddy, Praveen K.
author_facet Kaufman, Howard L.
Bommareddy, Praveen K.
author_sort Kaufman, Howard L.
collection PubMed
description Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) administration. While this may allow easy access to metastatic lesions, there is limited data supporting the therapeutic effectiveness of this approach. Further studies should include assessment of viral replication in tumor tissue and consider comparative trials using IV and intratumoral delivery to fully optimize oncolytic immunotherapy.
format Online
Article
Text
id pubmed-6359832
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63598322019-02-07 Two roads for oncolytic immunotherapy development Kaufman, Howard L. Bommareddy, Praveen K. J Immunother Cancer Commentary Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) administration. While this may allow easy access to metastatic lesions, there is limited data supporting the therapeutic effectiveness of this approach. Further studies should include assessment of viral replication in tumor tissue and consider comparative trials using IV and intratumoral delivery to fully optimize oncolytic immunotherapy. BioMed Central 2019-02-01 /pmc/articles/PMC6359832/ /pubmed/30709365 http://dx.doi.org/10.1186/s40425-019-0515-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Kaufman, Howard L.
Bommareddy, Praveen K.
Two roads for oncolytic immunotherapy development
title Two roads for oncolytic immunotherapy development
title_full Two roads for oncolytic immunotherapy development
title_fullStr Two roads for oncolytic immunotherapy development
title_full_unstemmed Two roads for oncolytic immunotherapy development
title_short Two roads for oncolytic immunotherapy development
title_sort two roads for oncolytic immunotherapy development
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359832/
https://www.ncbi.nlm.nih.gov/pubmed/30709365
http://dx.doi.org/10.1186/s40425-019-0515-2
work_keys_str_mv AT kaufmanhowardl tworoadsforoncolyticimmunotherapydevelopment
AT bommareddypraveenk tworoadsforoncolyticimmunotherapydevelopment

Ejemplares similares